Skip to main content
Clinical Trials/JPRN-UMIN000007185
JPRN-UMIN000007185Completed未知

Observational study of hand-foot syndrome events from XELOX therapy for metastatic colorectal cancer. - The study of metastatic colorectal cancer to investigate impact of learning effect.

Fujita Health University0 sites100 target enrollmentStarted: February 1, 2012Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
20years-old to 75years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1.Pleural effusion, peritoneal fluid and pericardial fluid. 2. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ. 3. Serious drug hypersensitivity or a history of drug allergy for Fluorouracil, leucovorin calcium or platinum agents. 4. Dihydropyrimidine Dehydrogenase Deficiency. 5. Evidence of interstinal lung disease, or pulmonary fibrosis. 6. Uncontrolled Active infection. 7. Difficulty on oral intake. 8. Other conditions not suitable for this study 9. Symptomatic brain metastasis. 10. Complication of cerebrovascular disease or symptoms within 1 year. 11. Any surgical treatments including skin open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week. 12. Planned surgery during this study. 13. Administering antithrombotic drug within 10 days. 14. Need to administrate or having anti-platelets therapy (including Methotrexate aspirin and NSAIDs). 15. Evidence of bleeding diathesis or coagulopathy. 16. Active gastrointestinal ulcer. 17. Renal failure to be treated, 2+ or higher proteinuria within 2 weeks prior to entry. 18. Uncontrolled Hypertension. 19. Clinically significant (i.e. active) cardiovascular disease, or past or current history (within the last 1 year) of myocardial infarction

Investigators

Similar Trials